Genovis ABOSTO:GENO -1.68%93 Gross Margin % is 88.53% as of Mar. 2026, which is 3% below its 10-year median of 91.57. GuruFocus rates OSTO:GENO with a GF Score™ of 93/100 and a GF Value™ of kr28.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Genovis AB ranks better than 84.15% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Genovis AB's Gross Profit for the
three
months ended in Mar. 2026 was kr29.7 Mil. Genovis AB's Revenue for the
three
months ended in Mar. 2026 was kr33.5 Mil. Therefore, Genovis AB's Gross Margin % for the quarter that ended in Mar. 2026 was 88.53%.
The historical rank and industry rank for Genovis AB's Gross Margin % or its related term are showing as below:
OSTO:GENO'
s Gross Margin % Range Over the Past 10 Years
Min: 85.33 Med: 91.57 Max: 97.59
Current: 89.52
During the past 13 years, the highestGross Margin % of Genovis AB was 97.59%. The lowest was 85.33%. And the median was 91.57%.
OSTO:GENO's Gross Margin % is ranked better than 84.15% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs OSTO:GENO: 89.52
Genovis AB had a gross margin of 88.53% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Genovis AB was -0.50% per year.
Genovis AB (OSTO:GENO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genovis AB had a gross margin of 88.53% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genovis AB Gross Margin % Related Terms
Genovis AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genovis AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Genovis AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genovis AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genovis AB (OSTO:GENO) has a Gross Margin % of 88.53% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Genovis AB and its competitors. This is near median its historical median of 91.57. Over the past decade, Genovis AB's Gross Margin % has ranged from 85.33 to 97.59. According to the industry distribution chart, Genovis AB ranks #116 out of 732 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Genovis AB's Gross Margin % too high?
Genovis AB's current Gross Margin % of 88.53% is near median its 10-year median of 91.57. Over the past 10 years, this metric has ranged from a low of 85.33 to a high of 97.59. The Biotechnology industry median Gross Margin % is 60.91. Genovis AB's value of 88.53% is 45.3% above this industry median. Based on the distribution chart, Genovis AB ranks #116 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovis AB has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #116 out of 732 companies for Gross Margin %. This places Genovis AB in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Genovis AB's value of 88.53% is 45.3% above this benchmark. Historically, Genovis AB's own Gross Margin % has ranged from 85.33 to 97.59 over the past decade. While the company's 10-year median is 91.57 vs. the industry median of 60.91, Genovis AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovis AB's current Gross Margin % of 88.53% is 45.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genovis AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current Gross Margin % is 88.53%, which is near median its own 10-year median of 91.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr28.59, compared to a current price of kr20.45 — trading 28.5% below its estimated fair value. The current Gross Margin % is 88.53%, which is near median its 10-year median of 91.57 and 45.3% above the Biotechnology industry median of 60.91. Genovis AB's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Gross Margin % is 88.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr20.45 is trading 28.5% below its estimated GF Value™ of kr28.59.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for OSTO:GENO:
Gross Margin %: 88.53% (near median its 10-year median of 91.57)
GF Value™: kr28.59 vs. price of kr20.45 (28.5% below fair value)
Industry Position: 45.3% above the Biotechnology median (#116 of 732)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
93GF Score
Get the complete analysis for OSTO:GENO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
